We are live on ! Find out more
BG

Bellevue Group Portfolio holdings

AUM $4.2B
1-Year Est. Return 54.85%
This Fund
S&P 500
This Quarter Est. Return
+3.94%
1 Year Est. Return
+54.85%
3 Year Est. Return
+140.3%
5 Year Est. Return
+171.01%
10 Year Est. Return
+915.55%
AUM
$9.45B
AUM Growth
+$719M
Cap. Flow
+$643M
Cap. Flow %
6.8%
Top 10 Hldgs %
29.09%
Holding
237
New
15
Increased
96
Reduced
78
Closed
21

Top Buys

Rank Stock Value
1
ACCD
Accolade Inc
ACCD
+$56.6M
2
RVMD icon
Revolution Medicines
RVMD
+$46M
3
SILK
Silk Road Medical, Inc. Common Stock
SILK
+$43.7M
4
EPIX
ESSA Pharma
EPIX
+$42.4M
5
BDX icon
Becton Dickinson
BDX
+$33.4M

Top Sells

Rank Stock Value
1
GWPH
GW Pharmaceuticals Plc American Depositary Shares
GWPH
+$86.9M
2
HALO icon
Halozyme
HALO
+$47.2M
3
GNMK
GenMark Diagnostics, Inc
GNMK
+$38.1M
4
ESPR
Esperion Therapeutics
ESPR
+$33.9M
5
CHNG
Change Healthcare Inc. Common Stock
CHNG
+$33.3M

Sector Composition

Rank Sector Weight
1 Healthcare 95.93%
2 Industrials 0.88%
3 Technology 0.47%
4 Consumer Discretionary 0.04%
5 Financials 0.04%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
QTRX icon
76
Quanterix
QTRX
$184M
$40.8M 0.43%
697,432
-15,567
-2% -$1.05M
BAX icon
77
Baxter International
BAX
$11.4B
$40M 0.42%
474,623
– –
GMED icon
78
Globus Medical
GMED
$10.3B
$39.9M 0.42%
647,509
+62,897
+11% +$3.98M
VEEV icon
79
Veeva Systems
VEEV
$32.1B
$39.9M 0.42%
152,800
+40,859
+37% +$11.4M
DVA icon
80
DaVita
DVA
$15B
$39.6M 0.42%
367,600
+14,400
+4% +$1.6M
MDT icon
81
Medtronic
MDT
$107B
$39.3M 0.42%
332,522
-128,736
-28% -$15.1M
NEO icon
82
NeoGenomics
NEO
$1.85B
$38M 0.4%
787,953
+239,507
+44% +$12.5M
HZNP
83
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
$37.6M 0.4%
408,500
+28,300
+7% +$2.39M
HCAT icon
84
Health Catalyst
HCAT
$160M
$34.7M 0.37%
741,855
+121,645
+20% +$5.89M
ATRC icon
85
AtriCure
ATRC
$1.76B
$32.6M 0.35%
497,712
-58,662
-11% -$3.61M
AMWL icon
86
American Well
AMWL
$210M
$32.5M 0.34%
93,422
+46,314
+98% +$25.1M
ONEM
87
DELISTED
1Life Healthcare
ONEM
$32.2M 0.34%
823,135
+185,582
+29% +$8.71M
PHR icon
88
Phreesia
PHR
$660M
$31.9M 0.34%
613,013
+140,293
+30% +$8.84M
TMDX icon
89
Transmedics
TMDX
$2.54B
$30.8M 0.33%
742,200
+100,588
+16% +$3.1M
MASI
90
DELISTED
Masimo
MASI
$29M 0.31%
126,196
+18,372
+17% +$4.62M
EXAS
91
DELISTED
Exact Sciences
EXAS
$28.7M 0.3%
218,140
+23,140
+12% +$3.17M
HCM icon
92
HUTCHMED
HCM
$1.95B
$27.6M 0.29%
975,488
+27,814
+3% +$887K
KZR
93
DELISTED
Kezar Life Sciences
KZR
$27M 0.29%
453,315
– –
OPCH icon
94
Option Care Health
OPCH
$3.42B
$26.8M 0.28%
+1,508,320
New +$28.3M
COO icon
95
Cooper Companies
COO
$14B
$26.6M 0.28%
277,468
+103,428
+59% +$9.81M
NVRO
96
DELISTED
NEVRO CORP.
NVRO
$25.3M 0.27%
181,013
+50,611
+39% +$8.26M
ILMN icon
97
Illumina
ILMN
$27.9B
$23.4M 0.25%
62,624
+8,792
+16% +$3.58M
ONC
98
BeOne Medicines Ltd
ONC
$32.2B
$20.8M 0.22%
59,700
-47,400
-44% -$15.7M
NUAN
99
DELISTED
Nuance Communications, Inc.
NUAN
$20.5M 0.22%
+468,885
New +$21.6M
EAR
100
DELISTED
Eargo, Inc. Common Stock
EAR
$19.4M 0.21%
19,393
+9,567
+97% +$10.9M
2 3
4
5 6

Similar funds

WSFS
Wilmington Savings Fund Society Wilmington, Delaware $4.2B AUM 18.37% 1-Year Est. Return
AC
AlphaCore Capital La Jolla, California $4.22B AUM 21.28% 1-Year Est. Return
HIP
HUB Investment Partners Austin, Texas $4.18B AUM 24.76% 1-Year Est. Return
DT
DV Trading Chicago, Illinois $4.22B AUM
ATPW
Ashton Thomas Private Wealth Scottsdale, Arizona $4.23B AUM 20.9% 1-Year Est. Return
BT
Banque Transatlantique Paris, France $4.17B AUM 28.5% 1-Year Est. Return
NCM
Nearwater Capital Markets Dublin 4, Dublin, Ireland $4.24B AUM 66.03% 1-Year Est. Return
MSU
Mizuho Securities USA New York $4.24B AUM 23.1% 1-Year Est. Return

Bellevue Group's Q1 2021 Portfolio in Review

As of Q1 2021, Bellevue Group held 237 positions worth $9.45B, up 8.2% from $8.73B the previous quarter. Its ten largest holdings account for 29% of the portfolio.

Bellevue Group deployed $643M of net new capital in Q1 2021, opening 15 new positions and adding to 96 existing holdings. Its largest new stake was ESSA Pharma: 1,825,814 shares worth $53M.

By sector, the portfolio is most concentrated in Healthcare at 96% of assets, up from 96% a quarter earlier, followed by Industrials and Technology.

On the sell side, the largest reduction was GW Pharmaceuticals Plc American Depositary Shares, an estimated $86.9M trimmed.

  • Bellevue Group's largest Q1 2021 buy was ESSA Pharma: 1,825,814 shares worth $53M.
  • Bellevue Group added most to Accolade Inc in Q1 2021, an estimated $56.6M increase.
  • Bellevue Group's biggest Q1 2021 reduction was GW Pharmaceuticals Plc American Depositary Shares, cutting an estimated $86.9M.
  • Bellevue Group fully exited GenMark Diagnostics, Inc in Q1 2021, selling an estimated $38.1M.
  • Bellevue Group's ten largest holdings make up 29% of its $9.45B portfolio in Q1 2021.
  • Bellevue Group opened 15 new positions and closed 21 in Q1 2021.
  • Bellevue Group's portfolio value rose 8.2% quarter-over-quarter to $9.45B.

Based on Bellevue Group's 13F filing for Q1 2021, filed 12 May 2021.